Attached files
| file | filename |
|---|---|
| EX-10.52 - EX-10.52 - ARENA PHARMACEUTICALS INC | arna-ex1052_779.htm |
| EX-32.1 - EX-32.1 - ARENA PHARMACEUTICALS INC | arna-ex321_6.htm |
| EX-31.2 - EX-31.2 - ARENA PHARMACEUTICALS INC | arna-ex312_7.htm |
| EX-31.1 - EX-31.1 - ARENA PHARMACEUTICALS INC | arna-ex311_8.htm |
| EX-23.1 - EX-23.1 - ARENA PHARMACEUTICALS INC | arna-ex231_9.htm |
| EX-10.55 - EX-10.55 - ARENA PHARMACEUTICALS INC | arna-ex1055_997.htm |
| EX-10.53 - EX-10.53 - ARENA PHARMACEUTICALS INC | arna-ex1053_778.htm |
| 10-K - 10-K - ARENA PHARMACEUTICALS INC | arna-10k_20161231.htm |
Exhibit 21.1
Subsidiaries of Arena Pharmaceuticals, Inc.
As of December 31, 2016
356 Royalty, Inc., a Delaware corporation
Arena Pharmaceuticals Development GmbH, a limited liability company organized under the laws of Switzerland and having its domicile in Zug
Arena Pharmaceuticals GmbH, a limited liability company organized under the laws of Switzerland and having its domicile in Zofingen
API Development LTD, a company incorporated in the Cayman Islands with limited liability